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Introduction
Hematopoietic stem cells (HSC) lie at the core of the hematopoietic 
and immune systems and have a unique capacity for self-renewal 
and differentiation to multipotent and lineage-committed hemato-
poietic progenitors, which give rise to mature cells of the myeloid and 
lymphoid lineages (1). Under steady-state conditions, HSCs remain 
mostly quiescent and have a limited function in the maintenance 
of hematopoiesis (1–3). However, HSCs promptly switch to a prolif-
erative state in order to meet the increased demands in response to 
hematopoietic stress, such as bone marrow (BM) injury, transplanta-
tion, or systemic infection (1, 3). The specialized micro-anatomical 
environment in the BM in which HSCs reside is designated the HSC 
niche and crucially regulates the homeostatic balance between quies-
cence, self-renewal, and differentiation of HSCs. Recent advances in 
BM imaging reveal a perivascular distribution of HSCs in their niche, 
which comprises several cell populations. Endothelial (4–11) and 
perivascular stromal cells (9, 12–14), including CXCL12-abundant 
reticular cells (CAR cells) (15, 16), are considered the main cell pop-
ulations constituting the homeostatic HSC niche, whereas osteolin-
eage cells and osteoblasts have a significant role in the post-transplant 
HSC niche (3, 17, 18). Niche cells regulate HSC homeostasis through 
paracrine growth factor and chemokine signals as well as via adhesive 
interactions (3, 5, 9, 19, 20).
Therapies targeting HSCs, including the administration of 
growth factors such as granulocyte colony–stimulating factor (G-CSF) 
and HSC transplantation, have revolutionized the clinical outcome in 
patients with malignancies or BM failure syndromes (21, 22). G-CSF–
based HSC mobilization is the main strategy used in both autologous 
and allogeneic transplantation (23). However, G-CSF administration 
fails to mobilize adequate numbers of HSCs for transplantation in a 
substantial number of healthy donors and patients (21, 23, 24), ren-
dering the development of additional mobilization strategies impera-
tive. Moreover, G-CSF is used as a prophylactic treatment in patients 
with increased risk for iatrogenic neutropenia (25, 26) and in the 
treatment of patients with congenital neutropenia (27, 28).
Developmental endothelial locus–1 (Del-1), a glycoprotein 
secreted by endothelial and certain other cells, becomes associated 
with the extracellular matrix or cellular surfaces and interacts with 
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es. We show that Del-1, via its interaction with the Įvȕ3 integ-
rin, promotes several critical functions in the niche, including 
HSC retention, hematopoietic progenitor cell cycle progres-
sion, and myeloid lineage commitment of HSCs. Del-1 there-
by regulates myelopoiesis under steady-state conditions and in 
G-CSF– or inflammation-induced stress myelopoiesis, as well as 
myelopoiesis reconstitution under regenerative/transplantation 
conditions. Del-1 is hence a niche component that serves a jux-
tacrine homeostatic adaptation of the hematopoietic system in 
inflammation-related and regeneration myelopoiesis.
Results
Del-1 expression in the BM. First, we sought to investigate whether 
Del-1 is present in the BM. We initially studied the expression of 
the Del-1–encoding gene Edil3 in the BM niche and hematopoietic 
cell populations. We found that Edil3 mRNA expression was sig-
nificantly higher in the endosteal region as compared with the cen-
tral BM (cBM) (Figure 1A), suggesting that Del-1 is enriched at the 
endosteal area of the BM. Analysis of sorted cells from CXCL12-
GFP mice (33, 34) demonstrated that Edil3 was highly expressed 
integrin receptors (29–31). It consists of three N-terminal EGF-like 
repeats and two C-terminal discoidin I–like domains, and hence 
also is designated EGF-like repeats and discoidin-I–like domains–3 
(EDIL3) (32). We have previously identified Del-1 as an endogenous 
modulator of leukocyte adhesion through interaction with integrin 
ĮLȕ2 (LFA-1; CD11a/CD18) (29, 31). Moreover, Del-1 interacts with 
ȕ3 integrin (CD61) via an Arg-Gly-Asp (RGD) motif on the second 
EGF-like repeat (30).
In the present work, we observed that Del-1 is expressed by 
several major cellular components of the HSC niche, though not 
by hematopoietic progenitors. In particular, Del-1 is expressed 
by those niche cells that have a major role in the maintenance 
of HSCs, i.e., arteriolar endothelial cells and perivascular CAR 
cells (3, 6, 7, 9, 15). In addition, Del-1 is expressed by cells of 
the osteoblastic lineage that crucially mediate the engraftment 
of HSCs in the post-transplantation niche (3, 17, 18). This spa-
tial distribution of Del-1 raised the possibility that it might be 
involved in the regulation of hematopoiesis. We addressed this 
hypothesis using in vivo models of steady-state, regenerative, 
and stress hematopoiesis and in vitro mechanistic approach-
Figure 1. Expression of Del-1 in HSC niche cell populations. (A) Edil3 mRNA levels in the cBM and endosteal region (n = 5 mice per group). (B) Edil3 mRNA 
levels in stromal cell populations from CXCL12-GFP mice: CD45–Ter119–CD31–GFPhi (CAR) cells, CD45–Ter119–CD31–GFP– MSCs, and CD45–Ter119–CD31+GFPint 
endothelial cells (EC; n = 3–4). The mRNA expression was normalized against ȕ2M. (C) Gating strategy for the isolation of endothelial cells. After gating on 
CD45–Lin– cells, sinusoidal (sBMEC; CD31+Sca1–) and arteriolar (aBMEC; CD31+Sca1+) BM endothelial cells were isolated. VE-cadherin (VE-cadh) staining was 
used to confirm the arteriolar origin of the CD31+Sca1+ cell population. Right: Edil3 mRNA levels in sBMECs and aBMECs (n = 3–4). mRNA expression was 
normalized against ȕ2M. (D) aBMECs were further sorted according to Vcam1 expression. Edil3 mRNA levels in Vcam1lo and Vcam1hi aBMECs as well as in 
CD45–Lin–CD31–Sca1–CD51+ OSL cells (n = 4–5). mRNA expression was normalized against ȕ2M. (E) Localization of Del-1 in the perivascular area of the BM; 
vessel lumen staining was performed with isolectin B4 (lectin). Del-1–deficient mice served as controls for the Del-1 staining. (F) Fluorescence microscopy 
image showing the presence of Del-1 in arterioles. Endothelial staining was performed using anti-PECAM1 and VE-cadherin antibodies. Scale bars: 5 ȝm. (G) 
EDIL3 mRNA in hMSCs and primary human osteoblasts (hOB) was compared with EDIL3 mRNA in HUVECs (HUVECs, n = 4 independent cultures; hMSCs,  
n = 4 donors; hOBs, n = 1 performed in technical replicates). The mRNA expression was normalized against GAPDH. (H) Del-1 concentration in culture super-
natants of hMSCs was assessed by ELISA (n = 4 donors). Data are presented as mean ± SEM. Mann-Whitney U test, *P < 0.05, **P < 0.01.
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and perivascular stromal cells, like CAR cells, (9, 14–16), and by 
cells that mediate the reconstitution of hematopoiesis after trans-
plantation, like OSL cells (3, 17, 18).
Del-1 promotes steady-state myelopoiesis. We next assessed 
whether Del-1 could affect hematopoietic progenitor maintenance 
and function. Specifically, to determine a possible functional role 
of Del-1 in the regulation of hematopoiesis, we performed BM anal-
ysis in adult Del-1–deficient (Edil3–/–) and Del-1–proficient (WT; 
Edil3+/+) mice. Although Del-1 deficiency had no significant effect 
on total BM cellularity (Figure 2A), it caused a significant decrease 
in the number of common myeloid progenitors (CMPs; Lin–cKit+ 
Sca1–CD16/32–CD34+) (Figure 2B) and megakaryocyte erythro-
cyte progenitors (MEPs; Lin–cKit+Sca1–CD16/32–CD34–) (Figure 
2C). The numbers of granulocyte macrophage progenitors (GMPs; 
Lin–cKit+Sca1–CD16/32+CD34+) were not significantly decreased in 
the BM of Edil3–/– mice as compared with Edil3+/+ mice (Figure 2D). 
Moreover, the use of a CFU assay revealed decreased numbers of 
functional progenitor cells (colony-forming cells [CFCs]) in the BM 
of Edil3–/– mice, as compared with Edil3+/+ mice (Figure 2E). The 
decrease in myeloid progenitor cells was associated with a signif-
icant decrease in the numbers of Gr1hiCD11b+ granulocytes (Figure 
2, F and G) and Gr1intCD11b+ myeloid cells (Figure 2, F and H) in the 
BM of Edil3–/– mice as compared with Edil3+/+ mice. In contrast, no 
difference was observed in the levels of G-CSF in peripheral blood 
(Supplemental Figure 2), in the number of different B cell popula-
tions, or in the numbers of common lymphoid progenitors (CLPs; 
Lin−Sca1locKitloFlt3+IL7RĮ+) in the BM due to Del-1 deficiency 
(Supplemental Figure 3). Since steady-state hematopoiesis is 
maintained by long-lived multipotent progenitors (2), we studied 
whether Del-1 deficiency had a quantitative and/or a qualitative 
effect on hematopoietic progenitors. No difference was seen in the 
in CAR cells (CD45–TER119–CD31–GFPhi) as compared with 
endothelial cells (CD45–TER119–CD31+ GFPint) and CXCL12-neg-
ative stromal cells (Figure 1B). Furthermore, analysis of sorted 
BM endothelial cells demonstrated that Edil3 is predominantly 
expressed in Lin–CD45–CD31+Sca1+ arteriolar BM endothelial cells 
(aBMECs) as compared with Lin–CD45–CD31+Sca1– sinusoidal BM 
endothelial cells (sBMECs) (Figure 1C) (6). The expression of VE- 
cadherin by the Lin–CD45–CD31+Sca1+ population further con-
firmed their arteriolar origin (Figure 1C) (6). Further analysis 
identified a Vcam1hi subpopulation within the aBMECs express-
ing the highest Edil3 mRNA levels (Figure 1D). Moreover, Del-1 
was expressed by Lin–CD45–CD31–Sca1–CD51+osteolineage (OSL) 
cells (Figure 1D). In contrast, Edil3 mRNA expression could not 
be detected in multipotent progenitors (MPPs; Lin–cKit+Sca1+ 
CD48+CD150–), long-term HSCs (LT-HSCs) (Lin–cKit+Sca1+CD48– 
CD150+), or other hematopoietic cell populations in the BM, such 
as Lin+ cells (data not shown). The spatial distribution of Del-1 in 
the perivascular area of the BM and its expression in the endothe-
lium of BM arterioles (diameter approximately 5 µm; ref. 6) were 
verified by immunostaining (Figure 1, E and F, and Supplemental 
Figure 1. We further evaluated the expression of Del-1 in primary 
human BM-derived mesenchymal stromal cells (hMSCs) and pri-
mary human osteoblasts (hOBs) by quantitative PCR. EDIL3 was 
highly expressed in hMSCs and hOBs, compared with HUVECs 
(Figure 1G), a cell population known to express substantial levels 
of EDIL3 (31, 35). Del-1 protein was also detected in culture super-
natants of primary hMSCs, further showing that Del-1 can be 
produced and released by stromal cells in the human BM micro-
environment (Figure 1H). Thus, Del-1 is expressed in the BM by 
distinct niche cell populations that promote HSC maintenance 
under steady-state conditions, including endothelial cells (4–7) 
Figure 2. Del-1 supports myeloid lineage development. (A) Total BM cell numbers in the BM of 10-week-old Edil3–/– and Edil3+/+ mice (n = 10 mice per 
group). (B) CMP, (C) MEP, and (D) GMP cell numbers in the BM of Edil3–/– (n = 13) and Edil3+/+ mice (n = 14). (E) CFCs in the BM of Edil3–/– and Edil3+/+ mice 
(n = 5 mice per group). (F) Representative flow cytometry plots and (G) Gr1hiCD11b+ granulocyte and (H) Gr1intCD11b+ myeloid cell numbers in the BM of 
10-week-old Edil3–/– (n = 9) and Edil3+/+ mice (n = 8). Data are presented as mean ± SEM. Mann-Whitney U test, *P < 0.05, **P < 0.01, ***P < 0.001.
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Together, these data suggest that Del-1 promotes steady-state 
myelopoiesis by regulating the bias of early hematopoietic pro-
genitors toward the myeloid lineage.
To assess whether the decreased numbers of myeloid progen-
itor cells in the BM of Edil3–/– mice were due to impaired retention 
of hematopoietic and myeloid progenitor cells in the BM, we ana-
lyzed LSK cells and myeloid progenitor cells in the spleen, as well 
as circulating LSK cells, myeloid progenitors (LK; Lin–Sca1–cKit+), 
and CFCs. We did not observe any difference in circulating pro-
genitors (Supplemental Figure 5, A–C), whereas the numbers and 
frequency of both LSK and LK cells were decreased in the spleen 
of Edil3–/– mice (Supplemental Figure 5, D–G). These data exclude 
the possibility that the decrease in myeloid progenitor cells in the 
Del-1–deficient BM was due to enhanced mobilization at steady 
state and, moreover, suggest a role for Del-1 in promoting HSC dif-
ferentiation toward the myeloid lineage.
Del-1 promotes the regeneration of myelopoiesis after hematopoi-
etic cell transplantation. We next studied whether Del-1 deficiency 
numbers of LSK (Lin–Sca1+cKit+) cells, LT-HSCs, short-term HSCs 
(ST-HSCs) (Lin–cKit+Sca1+CD48–CD150–), or MPPs (Supplemental 
Figure 4, A–E) between Edil3–/– and Edil3+/+ littermates. Therefore, 
the observed reduction in myelopoiesis due to Del-1 deficiency 
could not be attributed to an alteration in absolute cell numbers of 
hematopoietic progenitor populations in the BM.
Previous studies have shown that FLT3 (Flk2) expression can 
characterize MPPs with distinct lineage potential (36–38). Analy-
sis of FLT3 expression in MPPs from Edil3–/– mice revealed a sig-
nificant decrease in the percentage of the myeloid-biased FLT3– 
MPPs, as compared with Edil3+/+ mice (Supplemental Figure 4, F 
and G). Thus, although the total MPP numbers remained unaf-
fected due to Del-1 deficiency, we observed a qualitative differ-
ence in MPPs, which displayed a decreased bias toward myeloid 
differentiation. Consistent with this finding, gene expression 
analysis demonstrated a significant decrease in the mRNA levels 
of the myelopoiesis-related genes Cebpe, Csf1r, Csf2ra, and Irf8 
in CD48–LSK cells from Edil3–/– mice (Supplemental Figure 4H). 
Figure 3. Del-1 promotes regeneration of myelopoiesis. (A) Experimental design used to study the effect of Del-1 expressed in the BM of recipient mice on the 
long-term development of myelopoiesis upon hematopoietic cell transplantation. Lethally irradiated Edil3+/+ or Edil3–/– mice (CD45.2) were transplanted with 
CD45.1+ BM cells, as described in Methods. (B) Percentage of Gr1+CD11b+ myeloid and (C) CD19+ B cells in donor-derived cells in the peripheral blood of Edil3–/–  
(n = 10) and Edil3+/+ recipient mice (n = 9) at 16 weeks after transplantation. (D) Representative flow cytometry plots; (E) donor-derived Gr1hiCD11b+ granulocytes, 
(F) donor-derived Gr1intCD11b+ myeloid cells, and (G) donor-derived CD19+ B cells in the BM of recipient Edil3–/– (n = 10) or Edil3+/+ (n = 9) mice 16 weeks after trans-
plantation. (H) Percentage of Gr1+CD11b+ myeloid and (I) CD19+ B cells in donor-derived cells in the peripheral blood of Edil3–/– (n = 10) and Edil3+/+ recipient mice  
(n = 8) at different time points after secondary transplantation. Data are presented as mean ± SEM. Mann-Whitney U test, *P < 0.05, **P < 0.01.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
3 6 2 8 jci.org   Volume 127   Number 10   October 2017
poiesis in Edil3–/– compared with Edil3+/+ recipients (Figure 3, 
D–F), whereas the regeneration of the lymphoid lineage in the 
BM remained unaffected (Figure 3G). To definitively determine 
whether Del-1 can affect the long-term lineage bias of transplanted 
hematopoietic progenitors, we re-transplanted donor-derived 
cells (CD45.1+) from the Edil3+/+ recipient mice into second-
ary Edil3+/+ and Edil3–/– recipients. The observed impairment in 
myeloid lineage reconstitution in the peripheral blood of sec-
ondary Edil3–/– recipients was strikingly exacerbated (Figure 3, H 
and I), indicating that Del-1 in the BM drives the differentiation 
could affect the long-term lineage output of transplanted hema-
topoietic progenitors. To this end, we generated BM chimeras by 
transplanting CD45+ BM cells from congenic B6.SJL (CD45.1+) 
mice into lethally irradiated Edil3–/– or Edil3+/+ mice (CD45.2+) 
(Figure 3A). At 16 weeks after transplantation, we observed a sig-
nificant decrease in the percentage of donor-derived Gr1+CD11b+ 
myeloid cells in the peripheral blood of Edil3–/– compared with 
Edil3+/+ recipient mice (Figure 3B), with a corresponding increase 
in the percentage of B cells (Figure 3C). Analysis of BM revealed 
that this difference was due to impaired reconstitution of myelo-
Figure 4. Del-1 in recipient BM promotes the recovery of myelopoiesis. Lethally irradiated Edil3+/+ or Edil3–/– mice (CD45.2) were transplanted with CD45.1+ 
BM cells, as described in Methods. (A) Representative flow cytometry plots and (B) number of donor-derived LSK cells (CD45.1+) in the BM of recipient Edil3+/+ 
or Edil3–/– mice (CD45.2+) at 6 weeks after transplantation (n = 10 mice per group). (C) Representative flow cytometry plots and numbers of donor-derived (D) 
LT-HSCs, (E) ST-HSCs, and (F) MPPs in the BM of recipient Edil3+/+ or Edil3–/– mice at 6 weeks after transplantation (n = 10 mice per group). (G) Relative abun-
dance of the indicated cell populations (LT-HSCs, ST-HSCs, and MPPs) in the total LSK population is shown (CD48+CD150+ LSK cells were not considered). (H) 
Representative flow cytometry plots of cells gated on LK (see FACS plot in A); (I) donor-derived CMP and (J) donor-derived GMP cell numbers in the BM of 
recipient Edil3+/+ or Edil3–/– mice at 6 weeks after transplantation (n = 10 mice per group). Donor-derived (K) Gr1hiCD11b+ granulocytes, (L) Gr1intCD11b+ myeloid 
cells, and (M) CD19+ B cells in the BM of recipient Edil3+/+ or Edil3–/– mice at 6 weeks after transplantation (n = 10 mice per group). Data are presented as mean 
± SEM. Mann-Whitney U test, *P < 0.05, **P < 0.01, ***P < 0.001.
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of hematopoietic progenitors, particularly LT-HSCs, toward the 
myeloid lineage.
After transplantation, hematopoietic progenitor cells localize 
in proximity to blood vessels at the endosteal area of the BM (3, 
17, 18, 39), which could be attributed to irradiation-induced dis-
ruption of sinusoids, though not of endosteal arterioles (3). The 
expression of Del-1 in the peri-arteriolar region and by OSL cells, 
which also contribute to the restoration of hematopoiesis after 
transplantation, prompted us to further investigate in more detail 
how Del-1 supports the regeneration of myelopoiesis. To this end, 
we generated BM chimeras by transplanting CD45+ BM cells from 
congenic B6.SJL (CD45.1+) mice into lethally irradiated Edil3–/– or 
Edil3+/+ mice (CD45.2+) as above and performed BM analysis at 6 
weeks after transplantation. Del-1 deficiency in the BM impaired 
the expansion of donor-derived hematopoietic cells, as shown by 
the decreased numbers of donor-derived LSK cells (Figure 4, A 
and B), ST-HSCs (Figure 4, C and E), and MPPs (Figure 4, C and 
F), whereas LT-HSC numbers were not altered (Figure 4D). Del-1 
deficiency in recipients was associated with an increased percent-
age of donor-derived LT-HSCs and a concomitant decrease in the 
percentage of MPPs (Figure 4G), thus pointing to potentially 
diminished differentiation-associated proliferation of HSCs in the 
Del-1–deficient recipient environment. These findings were fur-
ther supported by a decrease in the numbers of myeloid progen-
itor cells, CMPs and GMPs, in Edil3–/– as compared with Edil3+/+ 
recipient mice (Figure 4, H–J). These data together suggest that 
Del-1 promotes the differentiation of hematopoietic progenitor 
cells into the myeloid lineage after transplantation. Additionally, 
Del-1 deficiency resulted in reduced numbers of Gr1hiCD11b+ 
granulocytes (Figure 4K) and Gr1intCD11b+ myeloid cells (Figure 
4L), whereas B cell numbers were not affected (Figure 4M). Upon 
transplantation, therefore, Del-1 promotes hematopoietic progen-
itor engraftment and differentiation toward the myeloid lineage.
Del-1 deficiency increases LT-HSC quiescence. Since normally 
there is a strong imbalance in the differentiation output of hemato-
poietic progenitor cells toward myelopoiesis compared with lymph-
opoiesis (2, 40), we next investigated whether Del-1 deficiency 
could affect the proliferation potential of hematopoietic progeni-
tors and thereby the progression of differentiation toward myeloid 
cell lineage. Cell cycle analysis revealed an increase in LT-HSC 
Figure 5. Del-1 promotes LT-HSC cell cycle progression. (A and B) Staining for Ki-67 nuclear antigen and DNA content (DAPI) was performed for cell cycle 
analysis. G
0
 phase is defined as Ki-67− and 2n DNA, G
1
 as Ki-67+ and 2n DNA, and S-G
2
-M as Ki-67+ and DNA >2n. (A) Representative flow cytometry plots 
and (B) cell cycle analysis in LT-HSCs from 10-week-old mice (n = 8 Edil3+/+ and n = 10 Edil3–/– mice). K, thousands. (C) Representative flow cytometry plots 
and (D) percentage of LT-HSCs that incorporated BrdU after 3 days of BrdU administration in drinking water (n = 5 mice per group). (E) Expression of Ccnd1, 
Ccng1, and Ccng2 in LT-HSCs from Edil3–/– and Edil3+/+ mice (n = 11–13 mice per group). mRNA expression was normalized against 18s. (F) BrdU pulse-chase 
assay protocol. BrdU was administered in drinking water for 15 days. Analysis of BrdU-retaining LT-HSCs was performed on day 70 after BrdU withdrawal  
(n = 5 mice per group). (G) Percentage of BrdU-retaining LT-HSCs in the BM of Edil3–/– and Edil3+/+ mice (n = 5 mice per group). Data are presented as mean ± 
SEM. Mann-Whitney U test, *P < 0.05, **P < 0.01.
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quiescence due to Del-1 deficiency, as shown by the increased per-
centage of LT-HSCs in G
0
 phase and the decreased percentage of 
LT-HSCs in the S/G
2
/M fraction in Edil3–/– mice (Figure 5, A and 
B). A BrdU incorporation assay further confirmed the decreased 
proportion of proliferating LT-HSCs in Edil3–/– mice (Figure 5, C 
and D). The increased quiescence of LT-HSCs from Edil3–/– mice 
compared with LT-HSCs from Edil3+/+ mice was associated with a 
downregulation in the gene expression of cyclins Ccnd1, Ccng1, and 
Ccng2 in Edil3–/– compared with Edil3+/+ mice (Figure 5E). Moreover, 
using a BrdU pulse-chase assay that can identify dormant LT-HSCs 
(41) (Figure 5F), we found increased frequency of BrdU-retaining 
(hence dormant) LT-HSCs on day 70 after BrdU withdrawal in 
Edil3–/– as compared with Edil3+/+ mice (Figure 5G), consistent with 
the increased quiescence of LT-HSCs in Del-1 deficiency.
Since the engraftment potential of hematopoietic progenitor 
cells mainly relies on the fraction of cells in the G
0
 phase of cell 
cycle (42, 43), we further assessed whether the enhanced quies-
cence of LT-HSCs from Edil3–/– mice could result in the increased 
engraftment capacity of these cells. To this end, we performed a 
competitive transplantation assay by transplanting equal num-
bers of donor BM cells derived from either Edil3–/– or Edil3+/+ mice 
(CD45.2+) and competitor cells (CD45.1+) into lethally irradiated 
recipients (CD45.1+) (Figure 6A). Peripheral blood analysis at 16 
weeks after transplantation revealed a significantly increased 
number of reconstitution units (R.U.) in the BM of Edil3–/– donors 
as compared with their Edil3+/+ counterparts (Figure 6, B and C). 
We further assessed the lineage bias of donor cells and observed 
a decreased frequency of donor-derived (CD45.2+) Gr1+CD11b+ 
myeloid cells in the blood of recipients transplanted with cells from 
Edil3–/– mice (Figure 6, D and E). Analysis of the BM chimerism in 
recipient mice further confirmed the increased long-term recon-
stitution efficiency of progenitors derived from Edil3–/– donors 
(Figure 6F). Additionally, we observed a decreased frequency of 
Gr1+CD11b+ myeloid cells (Figure 6, G and H) and a corresponding 
increase in the frequency of CD19+ B cell (Figure 6, I and J) in the 
donor-derived cell population in the BM of recipients transplanted 
with cells from Edil3–/– mice. Thus, the increased quiescence of 
LT-HSCs due to Del-1 deficiency results in enhanced repopulation 
activity of these cells and is associated with decreased myeloid 
differentiation potential of long-term repopulating cells.
ȕ3 Integrin mediates Del-1–dependent LT-HSC proliferation and 
myeloid differentiation. Having demonstrated that Del-1 promotes 
cell cycle progression and myeloid differentiation of hematopoietic 
progenitors, we set out to address the underlying mechanisms. 
Through cell-cell and cell-matrix interactions, integrins act as 
mechanosensors that initiate cell cycle progression via regulation 
of the levels of cyclins and cyclin-dependent kinase inhibitors (44, 
45). In previous studies, we identified the integrins ĮLȕ2 (CD11a/
CD18) and Įvȕ3 (CD51/CD61) as Del-1 receptors (29–31). There-
fore, we employed an adhesion assay to determine whether any 
of these integrins on hematopoietic progenitors mediates interac-
tion with Del-1. Blocking the ȕ3 integrin subunit with anti-CD61 
antibody significantly diminished LSK cell adhesion to immobi-
lized Del-1, whereas blockade of CD11a or CD49d had no effect 
(Figure 7A). We therefore next analyzed CD61 expression on 
hematopoietic progenitors with flow cytometry and found that 
CD61 was highly expressed on LT-HSCs and to a lesser extent 
on MPPs (Figure 7, B and C), which is in accordance with earlier 
studies (46, 47). To test the hypothesis that the interaction of Del-1 
with the Įvȕ3 integrin on hematopoietic progenitors regulates cell 
cycle−related gene expression, we cultured isolated LSK cells on 
immobilized Del-1 expressed as an Fc fusion protein (Del-1−Fc) 
or Del-1[RGE]−Fc, a point mutant that precludes interaction with 
Įvȕ3 integrin due to a Glu (E) for Asp (D) substitution in the critical 
Figure 6. Del-1 deficiency enhances long-term reconstitution capacity and lineage bias of LT-HSCs. (A) Competitive repopulation assay: BM cells from either 
Edil3–/– or Edil3+/+ mice (CD45.2+; donor) and CD45.1+ BM cells as competitors were transplanted into B6.SJL recipient mice (CD45.1+). (B) Representative flow 
cytometry plots of donor-derived chimerism in the peripheral blood of recipient mice at week 16 after transplantation and (C) number of R.U. per femur of 
Edil3–/– or Edil3+/+ donor mice (n = 10 recipients per group). (D) Representative flow cytometry plots and (E) percentage of donor-derived (CD45.2+) Gr1+CD11b+ 
myeloid cells in the blood of recipient mice. (F) Frequency of donor-derived cells in the BM of recipient mice at 16 weeks after transplantation (n = 10 recipients 
per group). (G) Representative flow cytometry plots and (H) percentage of donor-derived (CD45.2+) Gr1+CD11b+ myeloid cells in the BM of recipient mice (n = 10 
recipients per group). (I) Representative flow cytometry plots and (J) percentage of donor-derived CD19+ B cells in the BM of recipient mice at 16 weeks after 
transplantation (n = 10 recipients per group). Data are presented as mean ± SEM. Mann-Whitney U test, *P < 0.05, **P < 0.01, ***P < 0.001.
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tion of Ccnd1. To independently confirm that signaling induced 
through Del-1 ligation of Įvȕ3 integrin was responsible for regu-
lating cyclin D1 expression, we used an inhibitor of integrin-linked 
kinase (ILK), which mediates integrin-dependent outside-in sig-
RGD motif. Fc protein was used as a negative control. In contrast 
to the WT molecule, the RGE point mutant failed to induce Ccnd1 
gene expression in LSK cells (Figure 7, D and E), thus indicating 
a requirement for Įvȕ3-dependent adhesion to Del-1 for induc-
Figure 7. Įvȕ3 mediates the interaction of hematopoietic progenitors with Del-1. (A) Inhibition of LSK cell adhesion onto immobilized Del-1 by anti-CD61 
(anti-ȕ3) but not by anti-CD11a antibody or anti-CD49d antibody using a static adhesion assay (n = 3–4 independent experiments). Appropriate isotype control 
antibodies were used; cell adhesion in the presence of isotype controls was set as 1. (B and C) Expression of CD61 (ȕ3 integrin) on hematopoietic progenitor cells 
was studied by flow cytometry. (B) Representative histograms and (C) median fluorescent intensity (MFI) are shown (n = 5). (D) Ccnd1 expression in LSK cells 
cultured for 3 hours on Fc-control protein, Del-1−Fc, or Del-1−Fc mutated in the RGD motif (Del-1[RGE]–Fc) (n = 5 independent experiments). Ccnd1 expression in 
LSK cells is shown relative to control (Fc-control protein [Fc-ctrl]). (E) Effect of ILK inhibition [ILK inh] in Del-1–dependent upregulation of Ccnd1 expression  
(n = 4 independent experiments). DMSO was used as control. Ccnd1 expression in LSK cells is shown relative to Del-1–Fc in the presence of DMSO. (F) Experi-
mental design for the differentiation assay. LT-HSCs from mice were cultured with Del-1−Fc or Fc-control or Del-1[RGE]–Fc (500 ng/ml each) in cell suspension 
cultures, and analysis was performed after 7 days. (G) Representative images of the colonies, (H) representative flow cytometry plots, and (I) percentage of 
GMPs (n = 4 cultures). Scale bars: 200 ȝm. (J) LT-HSCs were cultured with Del-1−Fc in the presence of a ȕ3 inhibitor or control peptide (25 ȝg/ml each) for 7 days, 
as described in F, and the percentage of GMPs was assessed by flow cytometry (n = 5 cultures). (K) Experimental design for the differentiation assay. LT-HSCs 
were cultured with Del-1−Fc or Fc-control (500 ng/ml each) for 48 hours, and (L) the percentage of MPPs was analyzed by flow cytometry (n = 5 cultures). (M) 
Accumulation of CFSE+ LSK cells in the BM of non-irradiated recipient Edil3–/– (n = 9) or Edil3+/+ mice (n = 11) 20 hours after adoptive transfer of CFSE-labeled Lin– 
cells from WT mice. Cell accumulation in the BM is expressed as the percentage of CFSE+ LSK in total LSK cells. (N) Accumulation of CFSE+ LSK cells in the BM of 
non-irradiated recipient Edil3+/+ mice at 20 hours after adoptive transfer of CFSE-labeled Lin– cells from WT mice pretreated with a ȕ3 inhibitor (n = 6) or control 
peptide (n = 8 mice), as described in Methods. (O) Accumulation of CFSE+ LSK cells in the BM of non-irradiated recipient Edil3–/– mice at 20 hours after adoptive 
transfer of CFSE-labeled Lin– cells from WT mice pretreated with a ȕ3 inhibitor or control peptide (n = 7 mice per group). Cell accumulation in the BM is shown 
as relative to control peptide (ctrl) in N and O. Data are presented as mean ± SEM. Student’s paired t test was used in A, J, and L. One-way ANOVA followed by 
Holm-Šidák’s multiple comparison test was used in D, E, and I. Mann-Whitney U test was used in M–O. *P < 0.05, **P < 0.01.
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it had no effect on the differentiation of MPPs or CMPs toward 
GMPs (Supplemental Figure 6). These experiments firmly estab-
lish that the direct interaction of LT-HSC with Del-1 instructs their 
differentiation toward the myeloid lineage.
We next addressed the in vivo relevance of the Del-1/ȕ3 inte-
grin interaction. To this end, we initially studied the role of Del-1 
in hematopoietic progenitor cell homing to the BM. Fluorescently 
labeled Lin– cells were transplanted to non-ablated Edil3–/– and 
Edil3+/+ mice, and the percentage of transferred LSK cells in the 
BM was assessed 3 or 20 hours later. Del-1 deficiency had no effect 
at the early time point (Supplemental Figure 7). Therefore, Del-1 
does not affect the initial recruitment of hematopoietic progen-
itors via the vasculature to the BM, consistent with the fact that 
Del-1 does not interact with or regulate the Į4ȕ1 integrin (29) (Fig-
ure 7A), which is required for this function (48). Intriguingly, at the 
20-hour time point, the percentage of transferred cells was signifi-
cantly decreased in Edil3–/– as compared with Edil3+/+ mice, hence 
implicating Del-1 in the homing of transplanted hematopoietic 
progenitors (Figure 7M). To assess the significance of ȕ3 integrin–
dependent interactions of Del-1 in the BM, we tested whether this 
naling. We found that ILK inhibition abrogated the effect of the 
Įvȕ3–Del-1 interaction on Ccnd1 expression (Figure 7E). These 
findings reveal a role for Del-1 in regulating cyclin D1 expression 
in progenitors via interaction with Įvȕ3 integrin and integrin- 
dependent outside-in signaling events.
To further study whether Del-1 can drive the proliferation 
and differentiation of early progenitor cells, we performed an in 
vitro differentiation assay. LT-HSCs were treated with Fc-control, 
Del-1−Fc, or Del-1[RGE]−Fc in cell suspension cultures (Figure 
7F). Del-1–Fc (but not Fc-control) induced the proliferation and 
differentiation of LT-HSCs toward GMPs, whereas this effect was 
abolished when the RGE point mutant was used (Figure 7, G–I). 
Inhibition of ȕ3 integrins by a ȕ3 inhibitor, cilengitide, also abro-
gated LT-HSC differentiation on day 7 (Figure 7J), further suggest-
ing the involvement of ȕ3 integrins in Del-1−dependent induction 
of LT-HSC differentiation. To further determine whether Del-1 
acts on LT-HSCs or at later stages of differentiation, we treated 
LT-HSCs, MPPs, or CMPs for 48 hours with Fc-control or Del-1−Fc 
(Figure 7K and Supplemental Figure 6). We observed that Del-1 
induced the differentiation toward MPPs (Figure 7L), whereas 
Figure 8. Del-1 mediates the restoration of myelopoiesis in the BM upon LPS-induced inflammation. (A) Gr1hiCD11b+ granulocytes and (B) Gr1intCD11b+ 
myeloid cell numbers in the BM of Edil3+/+ or Edil3–/– mice at 24 hours (gray background) and at 72 hours following the second injection of LPS (n = 4–10 
mice per group). (C) CMP, (D) LSK, (E) LT-HSC, (F) ST-HSC, and (G) MPP cell numbers in the BM of Edil3–/– and Edil3+/+ mice (n = 4–8 mice per group) at 24 
hours (gray background) and at 72 hours following the second injection of LPS. (H) Cell cycle analysis in LT-HSCs and (I) MPPs at 72 hours following the 
second injection of LPS (n = 5–7 mice per group). Data presented as mean ± SEM. Mann-Whitney U test. *P < 0.05.
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Integrin Įvȕ3 has been previously 
shown to mediate the maintenance of 
HSCs, although the natural ligand(s) 
required for this niche interaction were 
not identified (46, 47). Having shown 
that the Del-1/ȕ3 integrin interaction 
plays a role in the homing of hemato-
poietic progenitors into the BM, we then 
determined whether this interaction also 
contributes to the restoration of myelo-
poiesis after transplantation. For this 
purpose, CD45+ BM cells from Itgb3–/– 
mice were transferred into lethally 
irradiated Edil3–/– or Edil3+/+ mice, and 
BM analysis in the recipient mice was 
performed 6 weeks later (Supplemen-
tal Figure 8A). As this experiment was 
not done using the congenic CD45.1/
CD45.2 system, it was not possible to 
specifically study the reconstitution by 
donor-derived cells. For this reason, 
analysis was performed by determining 
the absolute cell numbers of different 
hematopoietic progenitor populations 
in the BM of recipient mice. Consistent 
with the above-described effects of ȕ3 
integrin inhibition, in the absence of 
ȕ3 integrin on donor cells, Del-1 defi-
ciency in recipients failed to affect 
the number of LSK cells, myeloid pro-
genitors, or Gr1hiCD11b+ granulocytes 
and Gr1intCD11b+ myeloid cell popu-
lations (Supplemental Figure 8, B–F). 
These findings stand in stark contrast 
to the negative effect of Del-1 defi-
ciency on myelopoiesis reconstitution 
upon transplantation of ȕ3 integrin– 
sufficient donor cells (Figure 4). There-
fore, ȕ3 integrin is required for the 
Del-1–mediated progenitor engraft-
ment and reconstitution of myelopoie-
sis after transplantation.
Del-1 promotes the response of hema-
topoietic progenitors to systemic inflam-
mation. The above-documented func-
tion of Del-1 in steady-state myelopoiesis and in the regeneration 
of the myeloid lineage after transplantation prompted us to inves-
tigate its possible involvement in the response of hematopoietic 
progenitors to stress granulopoiesis, such as in models induced by 
LPS or G-CSF.
Administration of high-dose LPS is widely used to mimic the 
effect of systemic microbial infection on granulopoiesis, which 
forces LSK proliferation to compensate for the increased need 
for mature myeloid cells and restore BM cellularity (49–51). We 
therefore engaged this model to investigate whether Del-1 in the 
niche regulates the potential for myeloid lineage replenishment 
in the BM. To this end, Edil3–/– or Edil3+/+ mice were intraperito-
integrin mediates the enhanced homing of hematopoietic progen-
itors to the Del-1–proficient BM relative to the Del-1–deficient BM 
environment. To this end, fluorescently labeled Lin– cells from WT 
mice were transplanted to Edil3–/– or Edil3+/+ littermates, together 
with a ȕ3 inhibitor (cilengitide) or control peptide. Upon trans-
plantation into Edil3+/+ mouse recipients, inhibition of ȕ3 integrin 
decreased the homing of LSK cells to the BM, as compared with 
control treatment (Figure 7N). In contrast, ȕ3 inhibition did not 
affect the homing of LSK to the BM of Edil3–/– recipients (Figure 
7O), suggesting that ȕ3 integrin and Del-1 lie in the same pathway 
and contribute to the same homing mechanism for hematopoietic 
progenitors to the BM.
Figure 9. Role of Del-1 in the response of hematopoietic progenitor cells to G-CSF administration. (A) 
Total cell numbers and (B) LSK, (C) LT-HSC, (D) ST-HSC, (E) MPP, (F) CMP, and (G) GMP cell numbers in the 
BM of Edil3–/– and Edil3+/+ mice (n = 6 per group) at the end of the G-CSF administration protocol. (H) CFCs 
from the BM of Edil3–/– (n = 6) and Edil3+/+ mice (n = 5) at the end of the G-CSF administration protocol. 
(I) Representative flow cytometry plots and (J) numbers of mobilized LSK cells in the peripheral blood of 
Edil3–/– (n = 10) and Edil3+/+ mice (n = 11) at the end of the G-CSF administration protocol. (K) Number of 
CFCs in the peripheral blood of Edil3–/– and Edil3+/+ mice (n = 5-6 mice) at the end of the G-CSF administra-
tion protocol. Data are presented as mean ± SEM. Mann-Whitney U test, *P < 0.05, **P < 0.01.
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centage of GMPs and LSK cells in the BM after 6 daily injections of 
G-CSF was expressed relative to the percentage of GMPs and LSK 
cells in the BM after 6 daily injections of PBS. The corresponding 
ratios were then compared between Edil3–/– and Edil3+/+ mice. We 
observed that the expansion of GMPs in the BM of Edil3+/+ mice 
was more robust compared with Edil3–/– mice (Supplemental Fig-
ure 12A). Additionally, the relative levels of LSK cells were also sig-
nificantly higher in Edil3+/+ mice (Supplemental Figure 12B).
As G-CSF is used as a mobilizing agent in the context of autol-
ogous or allogeneic transplant (21, 23), we examined whether 
the physical interaction between Del-1 and HSCs promotes their 
retention in the BM, thereby counteracting the mobilizing effect 
of G-CSF. G-CSF–dependent mobilization of hematopoietic pro-
genitor cells was more efficient in Del-1 deficiency, as shown by 
the increased numbers of LSK (Figure 9, I and J) and CFCs (Figure 
9K) in the peripheral blood of Edil3–/– mice. We did not observe 
any alterations in the expression of Edil3 in the endosteal region 
of mice by the end of the G-CSF administration protocol (data not 
shown). Since downregulation in the expression of HSC niche fac-
tors in MSCs and osteoblasts is an important event during G-CSF–
dependent mobilization (12, 57, 58), we assessed Cxcl12, Angpt1, 
and Kitl gene expression in the endosteal region of Edil3–/– and 
Edil3+/+ mice after 6 daily injections of G-CSF. We observed that 
the decrease in the mRNA levels of these factors followed the 
same pattern in Edil3+/+ and Edil3–/– mice (Supplemental Figure 
13). Therefore, the effect of Del-1 deficiency on G-CSF–induced 
mobilization cannot be attributed to alterations in the expression 
of other HSC niche factors. These findings overall indicate that 
Del-1 acts as a niche factor that supports hematopoietic progenitor 
retention in the BM upon G-CSF–induced mobilization.
Discussion
Herein, we detected that Del-1 was enriched in the perivascular 
area of the BM, expressed by critical cellular niche components. 
Moreover, Del-1, via its interaction with ȕ3 integrin on LT-HSCs, 
facilitated LT-HSC proliferation and differentiation toward the 
myeloid lineage under steady-state and hematopoietic stress con-
ditions. Our data therefore establish a role for Del-1 in the HSC 
niche microenvironment.
During steady-state hematopoiesis, Del-1 deficiency resulted 
in increased quiescence of LT-HSCs without affecting hematopoi-
etic progenitor cell numbers, which is in accordance with previous 
studies showing that deficiency of niche factors does not necessar-
ily have a quantitative effect on LT-HSCs (5, 59). Strikingly, how-
ever, Del-1 deficiency resulted in a significant decrease in myeloid 
cell populations. Steady-state myelopoiesis is mainly maintained 
by multipotent hematopoietic progenitor cells (2). Consistent 
with this finding, we detected a significant downregulation in the 
expression levels of myelopoiesis-related genes in CD48– LSK cells 
derived from Del-1–deficient mice. Moreover, Del-1 deficiency 
resulted in phenotypic changes in MPPs, leading to a decreased 
percentage of MPPs with low Flt3 expression, which have been 
previously shown to be biased toward differentiation into myeloid 
lineage (36–38). Del-1 deficiency was further shown to affect the 
lineage bias of LT-HSCs, as shown by competitive repopulation 
conditions. The enhanced engraftment potential of hematopoietic 
progenitors from Edil3–/– mice was linked to a diminished poten-
neally injected with ultra-pure LPS twice, with an interval of 48 
hours, and hematopoietic progenitors and myeloid lineage cells 
were analyzed at 24 hours and at 72 hours following the second 
injection (52, 53). In this model, the initial increase in peripheral 
blood myeloid cells (52, 53), associated with a decrease in the 
numbers of mature myeloid cells and CMPs in the BM, is followed 
by a prominent expansion of the myeloid cell compartment, as 
observed in Edil3+/+ mice at 72 hours after LPS administration (Fig-
ure 8, A and B). However, the restoration of myelopoiesis in the BM 
was significantly attenuated in Del-1 deficiency, as shown by the 
decreased numbers of Gr1hiCD11b+ granulocytes (Figure 8A) and 
Gr1intCD11b+ myeloid cells (Figure 8B) in Edil3–/– relative to Edil3+/+ 
mice. In the same vein, the numbers of CMPs were decreased in 
Edil3–/– compared with Edil3+/+ mice at 72 hours after LPS admin-
istration (Figure 8C). Furthermore, Del-1 deficiency resulted in 
relatively inefficient expansion of LSK cells caused predominantly 
by inefficient expansion of MPPs 24 hours after LPS injection, 
and these differences between Edil3–/– and Edil3+/+ mice were sus-
tained after 72 hours (Figure 8, D–G). The delay in the reconstitu-
tion of the myeloid lineage was also associated with an increase in 
the percentage of quiescent LT-HSCs and MPPs (Figure 8, H and 
I) after 72 hours. In contrast, no difference was observed in cell 
cycle progression of myeloid progenitor cells upon LPS injection 
due to Del-1 deficiency (data not shown). No alterations in G-CSF 
production, which plays a critical role in emergency granulopoi-
esis (54), were observed between Edil3–/– and Edil3+/+ mice (Sup-
plemental Figure 9). In addition, the expression of Edil3 in the 
BM was not altered after LPS administration (data not shown). 
Furthermore, we did not observe any difference in the number of 
LSK and LK cells in the peripheral blood or spleen between Del-1 – 
deficient and –proficient mice (Supplemental Figure 10). The data 
in toto demonstrate that Del-1 promotes myeloid cell replenish-
ment in the BM in the course of systemic inflammation.
Del-1 regulates hematopoietic progenitor proliferation and reten-
tion in response to G-CSF. Besides inducing myeloid progenitor 
maturation (54), G-CSF was previously shown to promote LSK 
cell expansion by affecting the LT-HSC cell cycle (55, 56). For this 
reason, adult Edil3–/– and Edil3+/+ mice were injected daily with 
G-CSF for up to 6 days. At 24 hours after a single G-CSF admin-
istration, the expansion of total BM cells (Supplemental Figure 
11A), Gr1hiCD11b+ granulocytes (Supplemental Figure 11B), and 
Gr1intCD11b+ myeloid cells (Supplemental Figure 11C) was less 
prominent in Edil3–/– than in Edil3+/+ mice. LSK cell, MPP, and 
CMP but not LT-HSC or ST-HSC numbers (Supplemental Figure 
11, D–H) were also decreased in Edil3–/– relative to Edil3+/+ mice. 
Cell cycle analysis of LT-HSCs from Edil3–/– and Edil3+/+ mice after 
3 daily injections of G-CSF revealed a decrease in the prolifera-
tion potential in HSCs derived from Edil3–/– mice (Supplemental 
Figure 11, I and J). By the end of the G-CSF administration course 
(6 days), BM cellularity (Figure 9A) and numbers of hematopoi-
etic and myeloid progenitors (Figure 9, B–G) were dramatically 
reduced in Edil3–/– mice as compared with Edil3+/+ mice. The 
decrease in phenotypical progenitor cells in Del-1 deficiency by 
the end of the G-CSF administration course was also associated 
with reduced counts of functional progenitor cells, as shown by a 
CFU assay (Figure 9H). To further evaluate whether Del-1 defi-
ciency affects myelopoiesis upon G-CSF administration, the per-
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of Ccnd1, whereas the interaction between Del-1 and Įvȕ3 integrin 
on hematopoietic progenitors results in increased Ccnd1 expres-
sion. The Del-1 deficiency–associated decreased gene expression 
of Ccnd1 in hematopoietic progenitors together with the in vitro 
stimulatory effect of Del-1 on Ccnd1 expression strongly corrobo-
rates the evidence presented here that Del-1 acts as a niche factor 
mediating differentiation-associated proliferation and myeloid 
lineage commitment of HSCs.
Several cellular components have been implicated as con-
tributing to homeostatic HSC niche function. Arteriolar vessels, 
comprising endothelial cells and a layer of mesenchymal stromal 
cells, promote the maintenance of LT-HSCs in a quiescent state (6, 
7, 13), although non-dividing stem cells have also been localized 
around sinusoids (6, 10). Endothelial and perivascular stromal 
cells, including CAR cells, support the maintenance of HSCs in the 
niche by producing stem cell factor, pleiotrophin, and CXCL12 (6, 
7, 9, 11–16) or by direct adhesive interactions through molecules, 
such as E-selectin (5). While expression of E-selectin is restrict-
ed to the endothelium, thus representing an endothelial-specific 
niche, Del-1 is expressed by several major cellular components 
in the niche microenvironment (CAR, arteriolar endothelial, and 
OSL cells). Therefore, Del-1 can act as a crucial HSC niche reg-
ulator in different settings. Indeed, by multiple complementary 
experimental approaches, we have demonstrated that Del-1 pro-
motes the retention of hematopoietic progenitors in the niche 
and orchestrates their proliferation and differentiation into the 
myeloid lineage under diverse conditions, ranging from steady-
state to regenerative and inflammation-related myelopoiesis. 
Thus, the demonstration of Del-1 as a factor governing the prolif-
eration and fate of LT-HSC provides mechanistic insights into how 
the HSC niche operates and contributes to homeostatic adaptation 
of the hematopoietic system. Interestingly, the adhesive interac-
tion between niche-expressed Del-1 and the Įvȕ3 integrin on 
LT-HSCs also constitutes an example of juxtacrine regulation of 
progenitor commitment toward the myeloid lineage. Our findings 
thereby identify what we believe to be a novel spatial component 
in the regulation of lineage fate and add to the growing evidence of 
distinct control of hematopoietic precursors within the BM.
Our findings establish a homeostatic role for Del-1 during 
inflammation via stimulation of myelopoiesis and production 
of mature effector cells. Therefore, the homeostatic function of 
Del-1 is not restricted to regulation of inflammatory cell recruit-
ment to peripheral tissues as we showed earlier (29, 31, 65), but 
also involves control of their progenitors in the BM. As febrile 
neutropenia, associated with chemotherapy or HSC transplanta-
tion, is a major cause for morbidity and mortality (25), the herein 
identified role of Del-1 in the induction and maintenance of proper 
de novo granulopoiesis is important and could be therapeutical-
ly exploited in this context. On the other hand, inhibition of the 
interaction of Del-1 with hematopoietic progenitor cells could be 
exploited pharmacologically to enhance progenitor mobilization 
in the context of autologous or allogeneic HSC transplantation or 
hematologic malignancy (66). The emergence of Del-1 as a critical 
niche factor that promotes hematopoietic progenitor expansion 
and retention, as well as myelopoiesis, suggests that this homeo-
static factor needs to be seriously considered in the context of BM 
transplantation or hematological disorders.
tial for production of myeloid cells, which is in line with recent 
studies showing an association between increased proliferation 
of LT-HSCs and myeloid differentiation bias (60, 61). In particu-
lar, HSC clones with high proliferation rates were recently shown 
to be biased toward myeloid differentiation, while another study 
revealed a correlation between the expression of cell cycle and 
DNA replication genes and that of myeloid differentiation genes 
(60, 61). Our findings that Del-1 regulated the proliferation poten-
tial and myeloid differentiation of LT-HSCs but not of MPPs or 
CMPs suggest that Del-1 likely promotes differentiation-associated 
proliferation of LT-HSCs, thereby enabling the response of hema-
topoiesis to increased needs for production of myeloid cells.
The effect of Del-1 deficiency on LT-HSC proliferation poten-
tial and myelopoiesis had a strong impact in distinct models of 
stress myelopoiesis, wherein induction of hematopoietic progen-
itor proliferation is required to effectively replenish BM cells (1, 
40). Using three different, clinically relevant models, we demon-
strated that Del-1 is essential for the proper hematopoietic pro-
genitor response with regard to myeloid cell reconstitution, after 
BM transplantation, G-CSF administration, and LPS-dependent 
inflammation. In all three models, Del-1 deficiency consistently 
compromised the ability of the niche microenvironment to sup-
port the proliferation and differentiation of LT-HSCs into the 
myeloid lineage. After hematopoietic cell transplantation, Del-1 
in the recipient niche promoted progenitor engraftment and the 
generation of both progenitors and mature cells of the myeloid 
lineage in a manner dependent upon ȕ3 integrin expression in 
hematopoietic cells. Similarly, Del-1 was found to contribute to 
the proliferative response of hematopoietic progenitor cells after 
G-CSF administration or LPS-driven inflammation. Moreover, 
Del-1 promoted the retention of hematopoietic progenitors in 
the BM upon G-CSF administration. The critical involvement of 
Del-1 in all these different models of stress myelopoiesis attests 
to the important regulatory role of Del-1 within the HSC niche for 
myeloid lineage commitment.
The Įvȕ3 integrin on LT-HSCs interacted with and mediated 
the Del-1–dependent progenitor retention in the BM and progen-
itor commitment toward the myeloid lineage. The Įvȕ3 integrin/
Del-1 interaction supported LT-HSC differentiation–associated 
proliferation, which involved the induction of cyclin D1 expres-
sion. Previous studies have shown that Įvȕ3 integrin is expressed 
in HSCs and supports the maintenance of HSC activity (46, 47), 
although the niche-relevant ligand(s) of Įvȕ3 were not deter-
mined. Integrin activation is tightly linked to cell survival and 
proliferation (45). Cell-cell or cell–extracellular matrix adhesion 
through integrins induces intracellular signaling pathways that 
enable cells to enter cell cycle (45). The expression of D-cyclins 
is controlled by the extracellular environment (62) and is essen-
tial for integrin-mediated progression through the G
1
 phase of the 
cycle (44, 63). The important role of cyclin D1 in LT-HSC function 
was further highlighted in a recent study where downregulation of 
cyclin D1 gene expression, due to alterations in cell metabolism, 
exerted a critical impact on normal and leukemic HSC function 
(64). Additionally, cyclin D1 expression has been previously asso-
ciated with HSC differentiation–associated proliferation (42). We 
demonstrate here that the decreased proliferation of LT-HSCs due 
to Del-1 deficiency in vivo is associated with reduced mRNA levels 
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Research Center Inc.). Del-1 concentration in culture supernatants was 
measured using a human EDIL3 DuoSet ELISA (R&D Systems).
BrdU incorporation and pulse-chase assay. For BrdU incorporation 
assay, BrdU was administered in drinking water for 3 days at a con-
centration of 0.5 mg/ml (5). For BrdU pulse-chase assay, BrdU was 
administered in drinking water for 15 days at a concentration of 0.5 
mg/ml. Drinking water was changed twice weekly. Water containing 
BrdU was replaced with regular water after the pulse period, and anal-
ysis was performed 70 days after BrdU withdrawal (41). Staining for 
BrdU was performed using the FITC BrdU Flow Kit (BD Biosciences) 
following the manufacturer’s instructions.
LPS and G-CSF administration. To assess the effect of G-CSF on 
hematopoietic progenitors, we injected mice subcutaneously with a 
daily dose of 250 ȝg/kg of recombinant human G-CSF (Amgen) in 
PBS (Life Technologies) or PBS as control for up to 6 days. For LPS- 
induced inflammation, mice were injected intraperitoneally with 35 
ȝg ultrapure LPS (E. coli 0111:B4; InvivoGen) twice, with a 48-hour 
interval, and sacrificed at 24 hours or at 72 hours following the sec-
ond injection. In the LPS model, only BM samples with viability >80 
% were included in analysis. Peripheral blood analysis was performed 
using a Sysmex XT-2000 blood analyzer (Sysmex Corp.).
Flow cytometry, sorting, and immunofluorescence. Cell analysis was 
performed with a FACSCanto II flow cytometer using FACSDiva 6.1.3 
software (BD) or FACS LSR II flow cytometer. BM cells were harvested 
from femurs by repeatedly flushing with PBS supplemented with 5% FBS 
(Life Technologies). Mouse spleens were homogenized, and single- 
cell suspensions were prepared after erythrocyte lysis with red blood 
cell lysis buffer (eBioscience). The analysis of BM and spleen cellulari-
ty was performed with MACSQuant (Miltenyi Biotec). The antibodies 
used for cell surface phenotype analysis are shown in Supplemental 
Table 1. Brilliant Violet 510 Streptavidin (BioLegend) was used for the 
detection of biotinylated antibodies. Cell viability was assessed using 
Hoechst 33258 (Life Technologies). Data analysis was performed 
using FlowJo (Tree Star) software.
Cell sorting was performed using a FACSAria cell sorter (BD). 
Enrichment of Lin– cells was performed prior to cell sorting by neg-
ative magnetic selection using a MidiMACS Separator (Miltenyi Bio-
tec). For this reason, cells were incubated with a lineage cocktail of 
biotinylated antibodies (Biotin-Conjugated Mouse Lineage Panel, BD 
Pharmingen) and subsequently with anti-Biotin MicroBeads (Miltenyi 
Biotec). To isolate endothelial cells, femurs and tibiae were crushed 
with a mortar and incubated for 30 minutes with collagenase type I (3 
mg/ml, Life Technologies) prior to enrichment of Lin– cells. Endothe-
lial cells were characterized as arteriolar endothelial cells (CD45–Lin–
CD31+Sca1+) and sinusoidal endothelial cells (CD45–Lin–CD31+Sca1–). 
Cells were further characterized according to Vcam1 expression, as 
Vcam1hi and Vcam1lo.
For isolation of CXCL12-expressing niche cells, femurs were 
flushed and incubated with 1 U ml−1 liberase (Roche Applied Science) 
and 12 mU ml−1 DNase I (Sigma-Aldrich) in HBSS for 30 minutes at 
37°C. Different subsets of CXCL12-expressing niche cells were iden-
tified by staining digested BM suspensions from Cxcl12GFP reporter 
mice with biotinylated antibodies against TER-119 and CD45 (clone 
30-F11; eBioscience), followed by incubation with streptavidin con-
jugated to DyLight 405 (Jackson ImmunoResearch Laboratories Inc.) 
and an anti-CD31 antibody (clone 390; eBioscience). High or interme-
diate levels of GFP in the CD45/TER119-negative fraction were used 
Methods
Animals and transplantation experiments. Edil3–/– mice in a C57BL/6 
background were previously described (29, 31). CXCL12-GFP mice 
were housed in a specific pathogen–free facility at Fundación CNIC 
and were previously described (33, 34). Mice deficient in ȕ3 integ-
rin (B6;129S2-Itgb3tm1Hyn/J; stock no. 004669) and C57BL/6-CD45.1 
B6.SJL-Ptprca Pepcb/BoyJ (B6/SJL) mice were from the Jackson Labo-
ratory. Sex- and age-matched mice were used.
To generate BM chimeras, a total of 2 × 106 CD45+ BM cells from 
B6/SJL (CD45.1) mice were retro-orbitally transplanted into lethally 
irradiated (9 Gy) Edil3–/– or Edil3+/+ (WT) littermate mice (CD45.2). 
Blood was collected at week 16 for analysis of donor-derived peripheral 
blood cells, and BM analysis was performed at 6 and 16 weeks after 
transplantation for the analysis of donor-derived (CD45.1) cell popu-
lations. At week 16 after transplantation, a total of 2 × 106 CD45.1+ BM 
cells from the Edil3+/+ recipient group were further transplanted into 
lethally irradiated (9 Gy) Edil3–/– or Edil3+/+ mice (CD45.2), and periph-
eral blood analysis of the frequency of different CD45.1+ cell popula-
tions was performed every 4 weeks. In additional experiments, 2 × 106 
CD45+ BM cells from Itgb3–/– mice (CD45.2) were retro-orbitally trans-
planted into lethally irradiated Edil3–/– or Edil3+/+ mice. The reconstitu-
tion of different cell populations in the BM of the recipient mice was 
analyzed at week 6 after transplantation.
For BM competitive repopulation assays, the CD45.1/CD45.2 con-
genic system was used. Equivalent volumes of BM cells (2.5% of cells 
derived from a femur) harvested from CD45.2+ donor mice (Edil3–/– and 
Edil3+/) were retro-orbitally transplanted into lethally irradiated B6/SJL 
(CD45.1) recipients along with 3 × 105 BM cells derived from B6/SJL 
mice (67). Peripheral blood chimerism was assessed at 16 weeks after 
transplantation. We calculated the number of injected R.U. per recipient 
mouse using the formula (D × C)/(100 – D), where D is the percentage 
of CD45.2+ blood leukocytes at 16 weeks in the recipient mice, and C 
is the number of competing CD45.1+ R.U. that were coinjected (C = 3, 
since 3 × 105 competing BM cells were injected). The number of R.U. per 
femur was calculated afterward (5, 68). Chimerism in BM cells was also 
analyzed at week 16. Analysis of the lineage output of donor-derived 
(CD45.2+) cells was further performed after gating on donor-derived 
cells. In all transplantation experiments, mice were kept on antibiotic- 
containing water for 2 weeks after irradiation.
To assess the effect of Del-1 in hematopoietic progenitor migra-
tion to and homing in the BM, 2 × 106 Lin– cells from Edil3+/+ mice 
were labeled with CFSE and were retro-orbitally transferred into non- 
irradiated Edil3–/– or Edil3+/+ littermate recipients. BM was analyzed 3 
or 20 hours after cell transfer. In other experiments, CFSE+ Lin– cells 
from Edil3+/+ mice were pretreated for 5 minutes with cilengitide (10 
mg/kg; Selleck Chemicals) (69) or RGD control peptide (10 mg/kg; 
Enzo Life Sciences, GRADSP) before their transfer into non-irradiated 
Edil3–/– or Edil3+/+ littermate recipients.
Primary human cells. Primary human MSCs from healthy donors were 
generated out of BM aspirates by applying plastic adherence and serial 
passaging, as previously described (70–74). MSCs of the second passage 
were cultured in 24-well culture plates in DMEM supplemented with 
10% FBS until reaching subconfluence, then the medium was changed 
to DMEM with 0.1% BSA (Sigma-Aldrich); supernatants were collected 
18 and 48 hours thereafter. HUVECs (Lonza) were cultured in complete 
EBM-2 medium (Lonza). Cell pellets from human osteoblasts were from 
PromoCell. Total RNA was extracted using TRI reagent (Molecular 
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R&D Systems) (10 ȝg/ml each), as described under Adhesion assay. 
MyeloCult medium supplemented with stem cell factor (20 ng/ml, 
PeproTech) was used for the incubation of LSK cells. Isolated LSK 
cells were incubated for 3 hours to study the mRNA levels of Ccnd1. To 
inhibit ILK, LSK cells were treated with the ILK inhibitor Cpd22 (2 ȝM; 
Merck Millipore), whereas DMSO was used as control.
In vitro differentiation assay. Sorted LT-HSCs (500 cells per well), 
MPPs (1,000 cells per well), or CMPs (1,000 cells per well) were 
cultured in suspension culture 96-well plates (Greiner Bio-One) in 
MyeloCult medium supplemented with stem cell factor (20 ng/ml, 
PeproTech). Del-1−Fc, Del-1[RGE]–Fc, or recombinant human IgG1 
Fc (Fc-control; R&D Systems) (500 ng/ml each) were added in the cul-
tures. To inhibit ȕ3 integrin, LT-HSCs were preincubated for 15 minutes 
before the addition of Del-1−Fc or Fc-control with cilengitide (25 ȝg/ml; 
Selleck Chemicals) or RGD control peptide (25 ȝg/ml; Enzo Life Scienc-
es, GRADSP). After 48 hours or on day 7, the frequency of progenitor 
cells was analyzed by flow cytometry. The images from the colonies 
were acquired using a Zeiss Observer Z.1 inverted microscope.
Real-time PCR. For RNA isolation, cells were directly sorted into 
RNA isolation buffer, and RNA isolation was performed using an RNeasy 
Plus Micro Kit (QIAGEN), according to the manufacturer’s instructions. 
RNA from the cBM and the endosteal region was collected using TRI 
reagent (Molecular Research Center Inc.), as previously described (5). 
Briefly, after repeatedly flushing the femurs into PBS supplemented with 
5% FBS, for the isolation of cBM cells, the bones were flushed twice with 
TRI reagent to collect RNA from the endosteal region. RNA was reverse- 
transcribed with the iScript cDNA Synthesis Kit (Bio-Rad). Quantitative 
PCR was performed by using the SsoFast EvaGreen Supermix (BioRad) 
and gene-specific primers in a CFX384 Real-Time PCR Detection System 
(Bio-Rad). Relative mRNA expression levels were calculated according to 
the ǻǻCt method upon normalization to 18s or ȕ2m for mouse samples 
and GAPDH for human samples.
CFU assay. CFU assay was performed using MethoCult GF M3434 
medium (Stemcell Technologies), according to the manufacturer’s 
instructions. Quantification of colony formation was performed using 
a STEMvision Instrument (Stemcell Technologies).
G-CSF measurement. G-CSF was measured in EDTA-plasma using 
a Mouse G-CSF DuoSet ELISA (R&D Systems), according to the man-
ufacturer’s instructions.
Statistics. All data are presented as mean ± SEM. Mann-Whitney U 
test was used for the comparison of two groups. In vitro comparison of 
matched groups was performed with a paired 2-tailed Student’s t test. 
For comparisons of multiple groups, 1-way ANOVA followed by Holm-
Šidák’s multiple comparisons test was used. All statistical analysis was 
performed using GraphPad Prism 6 (GraphPad Software Inc.). Signif-
icance was set at P < 0.05.
Study approval. Animal experiments were approved by the Landes-
direktion Sachsen, Germany; the Animal Care and Ethics Committee of 
the CNIC and regional authority of Madrid; and the Institutional Animal 
Care and Use Committee of the University of Pennsylvania. Primary 
human BM-derived MSCs (70, 72–74) were derived from BM aspirates 
from healthy donors after written informed consent was received and 
upon approval by the Ethics Committee of the Technische Universität 
Dresden.
Author contributions. IM designed the project, performed experi-
ments, analyzed and interpreted data, and wrote the manuscript; LSC 
performed experiments and analyzed data; RPS performed experiments 
to discriminate CAR cells (CD45–TER119–CD31–GFPhi), CXCL12+en-
dothelial cells (CD45–TER119–CD31+GFPint), and CD31– GFP– mesen-
chymal stromal cells (CD45–TER119–CD31–GFP–) (33, 34). Cells were 
sorted on a FACSAria (BD Biosciences) to >95% purity.
For immunofluorescence, tibiae were collected and fixed for 2 
hours in 4% paraformaldehyde. Bone decalcification was performed 
for 48 hours in Osteosoft (Merck Millipore), and bones were embed-
ded in optical cutting temperature compound (OCT; Tissue-Tek). 
Endothelial cell staining in decalcified bones was performed using 
an APC-conjugated anti-CD31/PECAM-1 (clone 390; eBioscience) 
antibody and Alexa Fluor 694–conjugated anti-CD144/VE-cadherin 
(clone BV13; BioLegend), as described previously (7). In other experi-
ments endothelial cell staining in bones was performed with a rat anti–
mouse CD144/VE-cadherin (clone 11D4.1; BD Biosciences) antibody, 
followed by a goat anti-rat antibody conjugated with Alexa Fluor 647 
(Thermo Fisher Scientific). In another set of experiments, staining of 
the vascular lumen was performed by administering an Alexa Fluor 
594–conjugated Isolectin GS-IB4 from Griffonia simplicifolia (Thermo 
Scientific), as described (75). Del-1 staining was performed with a rab-
bit anti–mouse Del-1 (Proteintech, catalog 12580-1-AP), followed by 
a goat anti-rabbit antibody conjugated with Alexa Fluor 488 (Thermo 
Scientific). Nuclear staining was performed with DAPI. Images were 
acquired with a Zeiss LSM 510 confocal microscope, an IX83 micro-
scope equipped with a Yokogawa CSU-X1 spinning disc confocal scan-
ner (Olympus), or a Nikon Eclipse Ni-E automated upright fluores-
cence microscope (Nikon).
Cell cycle analysis. For cell cycle analysis, BM cells were stained 
for cell surface markers as described in the previous paragraph, fixed 
using fixation/permeabilization buffer (eBioscience), and stained 
with anti–Ki-67 antibody. After washing, cells were stained with DAPI 
(Molecular Probes) and analyzed by flow cytometry.
Proteins. Del-1−Fc generation has been previously described (30). 
An RGE point mutant of Del-1−Fc, in which Glu (E) was substituted 
for Asp (D) in the RGD motif of the second EGF repeat (Del-1[RGE]–
Fc), was constructed by site-directed mutagenesis (QuickChange 
II mutagenesis kit; Agilent). Expression and purification were per-
formed as described (30).
Adhesion assay. Adhesion was performed as previously described 
with modifications (29, 76, 77). Nunc-Immuno MicroWell 96-well solid 
plates (Sigma-Aldrich) were coated overnight at 4°C with Del-1–Fc (10 
ȝg/ml) and washed twice with PBS, and blockade was performed with 
1% BSA in PBS for 1 hour. Sorted LSK cells were stained for 30 minutes 
with BCECF (1 ȝM, Life Technologies). After washing, cells were resus-
pended in HBSS supplemented with 2 ȝM Mn++ and incubated with 
10 ȝg/ml rat IgG2a, ț isotype control (clone RTK2758; BioLegend), a 
rat IgG2b, ț isotype control (clone RTK4530; BioLegend), Armenian 
hamster IgG (clone HTK888; BioLegend), anti-CD11a (clone M17/4; 
BioLegend), anti-CD49d (clone R1-2; BioLegend), or anti-CD61 
(clone 2C9.G2; BioLegend) for 15 minutes at 4°C. Cells were added to 
wells and incubated for 45 minutes at 37°C. Fluorescence was mea-
sured before (cell input) and after (adherent cells) washing, using a 
Synergy HT multi-mode microplate reader (Biotek Instruments). The 
percentage of adhesion is defined as the fluorescence of adherent cells 
divided by the fluorescence of cell input.
In vitro LSK cell incubation and Ccnd1 expression. Tissue culture 
96-well plates (Greiner Bio-One) were coated overnight at 4°C with 
Del-1−Fc, Del-1[RGE]–Fc, or recombinant human IgG1 Fc (Fc-control; 
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and analyzed and interpreted data; IK, ME, TK, MT, AZ, KR, TM, TG, 
PS, and MDS performed experiments; KH and BW (Penn) generated 
critical reagents and interpreted data; MvB, MW, and MB provided 
human MSCs and interpreted data; PV, TT, and AH interpreted data; BW 
(Dresden) designed experiments, interpreted data, supervised research, 
and edited the manuscript; GH supervised research, interpreted data, 
and edited the manuscript; TC conceived and designed the project, 
interpreted data, supervised research, and wrote the manuscript.
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